https://www.selleckchem.com/pr....oducts/Cyclopamine.h
Infections during first-line therapy for DLBCL are often associated with chemotherapy dose reductions and increased mortality. Systemic infections have also been suggested as beneficial promotors of immunological responses. However, whether there is an association between the timing of an infectious episode and outcome during treatment has not yet been clarified. We investigated how the occurrence and timing of infectious episodes during the 1st line of treatment for 'de novo' DLBCL influenced patient outcome. We used data on DLBCL
Like
Comment
Share
